Shares of Cephalon Inc., Frazer, rose today after an analyst said tumor fighter Treanda may reach $1 billion in annual sales, more than 10 times revenue last year.
Earlier, data had been reported supporting its use as an initial therapy for immune system cancers. Treanda is approved for patients with a slow-growing form of non-Hodgkins lymphoma that doesn't respond to other drugs.
The newest data on Treanda were reported over the weekend at the American Society of Hematology meeting in New Orleans.
"It could be a widely used alternative" to the chemotherapy standard, said David Amsellem, an analyst with Piper Jaffray & Co.